Anhui Anke Biotechnology Group Co Ltd

Anhui Anke Biotechnology Group Co Ltd maintains a strong liquidity position, with a current ratio of 3.74, indicating the company can cover its short-term liabilities more than three times over. The company's liquidity_fpt score is high, supported by a free cash flow of 333,664,440 CNY and a net cash position that is negative after subtracting total debt. The debt-to-equity ratio is 0.01, suggesting a conservative capital structure with minimal leverage.

The company's profitability is robust, with a return on equity (ROE) of 16.13% and a return on assets (ROA) of 13.25%, both exceeding the industry median for pharmaceutical firms. Gross profit of 1,985,890,110 CNY and operating income of 836,577,970 CNY reflect strong cost control and pricing power. Net income of 735,192,710 CNY demonstrates the company's ability to convert revenue into profit effectively.

Geographically, the company's revenue is concentrated in China, with no disclosed international operations. The company operates in a single business segment, focusing on biopharmaceuticals, which accounts for 100% of its revenue. This concentration may expose the company to regulatory and market risks specific to the Chinese pharmaceutical sector.

The company's growth trajectory is positive, with revenue of 2,646,519,770 CNY in the latest reporting period. While no forward-looking revenue guidance is provided, the company's strong cash flow and profitability suggest a stable growth outlook. Capital expenditures of -126,891,930 CNY indicate a reduction in investment, which may signal a shift toward optimizing existing operations rather than expansion.

The company faces moderate liquidity risk, as noted in the risk assessment, with a liquidity score of medium. The risk of dilution is low, supported by a stable share count and no recent signs of equity issuance. However, the company's net cash position is negative after subtracting total debt, which could limit its flexibility in capital allocation. Adjustments in the custom valuations reflect a conservative approach to valuation, with no significant upward or downward revisions.

Recent events include the disclosure of strong ESG performance, with a governance pillar score of 26.04 and a social pillar score of 9.74. The ESG controversies score of 100.00 indicates no major controversies, which is a positive signal for long-term sustainability. No recent filings or transcripts have been disclosed that suggest material changes in the company's operations or strategy.